Preserved renal perfusion during beta blockade by tertatolol with and without cyclooxygenase inhibition in normal humans. 1988

C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
Department of Intensive Care, Erasme University Hospital, Brussels, Belgium.

The systemic and renal hemodynamic effects of tertatolol, a new noncardioselective beta blocker without partial agonist activity, given alone or in combination with cyclooxygenase inhibition by acetylsalicylic acid (aspirin), were investigated in eight healthy volunteers. Tertatolol 5 mg, aspirin 1 g, tertatolol 5 mg together with aspirin 1 g and placebo were administered at 1-week intervals in a random order and in a double-blind fashion. Cardiac output was measured by Doppler echography and renal blood flow and glomerular filtration rate (GFR) by constant infusion techniques using (123I) iodohippurate and (51Cr) EDTA, respectively. Measurements were performed before and then successively 2 and 4 hours after oral intake of drugs or placebo. Tertatolol decreased cardiac output by 22% (P less than .05) and heart rate by 17% (P less than .05) without change in blood pressure, renal blood flow, and GFR. The same effects occurred when tertatolol was given together with aspirin. Either placebo or aspirin alone had no effect on systemic and renal hemodynamics. These results suggest that cardiac output is redistributed to the kidneys after tertatolol intake in normal humans. This favorable effect on renal hemodynamics is probably not mediated by a local release of vasodilating prostaglandins.

UI MeSH Term Description Entries
D008297 Male Males
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration

Related Publications

C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
March 1984, American journal of kidney diseases : the official journal of the National Kidney Foundation,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
January 1989, Archives internationales de pharmacodynamie et de therapie,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
April 1982, Journal of clinical pharmacology,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
November 1989, American journal of hypertension,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
March 1986, Clinical pharmacology and therapeutics,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
January 1986, American journal of nephrology,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
January 1987, Fundamental & clinical pharmacology,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
April 1994, British journal of clinical pharmacology,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
December 1987, The Journal of laboratory and clinical medicine,
C Reuse, and M Leeman, and J P Degaute, and M Abramowicz, and J F Prost, and R Naeije
October 2004, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!